Neuromarketers Are Studying Brain Scans to Influence Our Product Choices

Neuromarketers Are Studying Brain Scans to Influence Our Product Choices

A doctor looking at MRI scan results.

(© zinkevych/Fotolia)


Keep ReadingKeep Reading
Julia Gottwald
Julia Gottwald is the co-author of “Sex, Lies, and Brain Scans”, which won the BPS Popular Science Book Award 2017. She completed her PhD in Psychiatry at the University of Cambridge and also holds degrees in Neuroscience from the University of Oxford and Biochemistry from Free University (Germany). In 2016, she won the BAP Public Communication Prize. In 2017, she was awarded the Association of British Science Writers Best Student Journalist Award. She now works for the healthcare communications agency Havas Lynx in Manchester, UK.
How sharing, hearing, and remembering positive stories can help shape our brains for the better

Across cultures and through millennia, human beings have always told stories. Whether it’s a group of boy scouts around a campfire sharing ghost stories or the paleolithic Cro-Magnons etching pictures of bison on cave walls, researchers believe that storytelling has been universal to human beings since the development of language.

But storytelling was more than just a way for our ancestors to pass the time. Researchers believe that storytelling served an important evolutionary purpose, helping humans learn empathy, share important information (such as where predators were or what berries were safe to eat), as well as strengthen social bonds. Quite literally, storytelling has made it possible for the human race to survive.

Keep ReadingKeep Reading
Sarah Watts

Sarah Watts is a health and science writer based in Chicago.

A new type of cancer therapy is shrinking deadly brain tumors with just one treatment

MRI scans after a new kind of immunotherapy for brain cancer show remarkable progress in one patient just days after the first treatment.

Mass General Hospital

Few cancers are deadlier than glioblastomas—aggressive and lethal tumors that originate in the brain or spinal cord. Five years after diagnosis, less than five percent of glioblastoma patients are still alive—and more often, glioblastoma patients live just 14 months on average after receiving a diagnosis.

But an ongoing clinical trial at Mass General Cancer Center is giving new hope to glioblastoma patients and their families. The trial, called INCIPIENT, is meant to evaluate the effects of a special type of immune cell, called CAR-T cells, on patients with recurrent glioblastoma.

Keep ReadingKeep Reading
Sarah Watts

Sarah Watts is a health and science writer based in Chicago.